We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
-8.23%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$13.7M
Cap. Flow
+$21.9M
Cap. Flow %
9.32%
Top 10 Hldgs %
80.18%
Holding
22
New
2
Increased
4
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$9.51M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$6.29M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$4.99M
4
ETNB
89bio
ETNB
+$3.42M
5
COGT icon
Cogent Biosciences
COGT
+$3.41M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$3.93M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$1.35M
3
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
+$1.04M
4
TNGX icon
Tango Therapeutics
TNGX
+$498K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.02B
$31.4M 13.34%
3,481,042
+500,000
+17% +$3.41M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$28M 11.91%
2,914,250
+397,330
+16% +$4.99M
GERN icon
3
Geron
GERN
$970M
$23.4M 9.94%
15,096,342
+810,627
+6% +$1.15M
KURA icon
4
Kura Oncology
KURA
$1.13B
$21.4M 9.09%
1,167,642
+661,219
+131% +$9.51M
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$17.4M 7.4%
5,905,400
– –
ACRS icon
6
Aclaris Therapeutics
ACRS
$885M
$16M 6.79%
1,144,939
– –
VRDN icon
7
Viridian Therapeutics
VRDN
$2.61B
$15.2M 6.46%
1,314,000
– –
KDNY
8
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.9M 5.92%
796,460
-85,893
-10% -$1.35M
JBIO
9
Jade Biosciences
JBIO
$1.33B
$13.9M 5.91%
25,416
– –
TRDA icon
10
Entrada Therapeutics
TRDA
$273M
$8.08M 3.43%
663,694
– –
MRUS
11
DELISTED
Merus
MRUS
$6.79M 2.89%
300,000
– –
TYRA icon
12
Tyra Biosciences
TYRA
$1.49B
$6.41M 2.72%
896,418
– –
AKUS
13
DELISTED
Akouos Inc
AKUS
$6.33M 2.69%
1,350,006
– –
TNGX icon
14
Tango Therapeutics
TNGX
$3.94B
$5.31M 2.26%
1,172,250
-82,250
-7% -$498K
MLTX icon
15
MoonLake Immunotherapeutics
MLTX
$1.28B
$5.25M 2.23%
+1,000,000
New +$6.29M
ALPN
16
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.92M 2.09%
578,260
-455,962
-44% -$3.93M
ETNB
17
DELISTED
89bio
ETNB
$3.65M 1.55%
+1,133,196
New +$3.42M
ZLAB icon
18
Zai Lab
ZLAB
$2.93B
$3.29M 1.4%
95,000
– –
DNTH icon
19
Dianthus Therapeutics
DNTH
$5.92B
$2.55M 1.08%
132,758
– –
ANAB icon
20
AnaptysBio
ANAB
$1.67B
$1.19M 0.5%
58,515
– –
ELEV
21
DELISTED
Elevation Oncology
ELEV
$777K 0.33%
555,000
– –
PRDS
22
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$181K 0.08%
59,039
-170,061
-74% -$1.04M

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q2 2022 Portfolio in Review

As of Q2 2022, TCG Crossover Management held 22 positions worth $235M, down 5.5% from $249M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

TCG Crossover Management deployed $21.9M of net new capital in Q2 2022, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 1,000,000 shares worth $5.25M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Alpine Immune Sciences Inc, an estimated $3.93M trimmed.

  • TCG Crossover Management's largest Q2 2022 buy was MoonLake Immunotherapeutics: 1,000,000 shares worth $5.25M.
  • TCG Crossover Management added most to Kura Oncology in Q2 2022, an estimated $9.51M increase.
  • TCG Crossover Management's biggest Q2 2022 reduction was Alpine Immune Sciences Inc, cutting an estimated $3.93M.
  • TCG Crossover Management's ten largest holdings make up 80% of its $235M portfolio in Q2 2022.
  • TCG Crossover Management opened 2 new positions and closed 0 in Q2 2022.
  • TCG Crossover Management's portfolio value fell 5.5% quarter-over-quarter to $235M.

Based on TCG Crossover Management's 13F filing for Q2 2022, filed 15 Aug 2022.